1. Academic Validation
  2. Development of the First-in-Class FEM1B-Recruiting Histone Deacetylase Degraders

Development of the First-in-Class FEM1B-Recruiting Histone Deacetylase Degraders

  • J Med Chem. 2025 Jan 23;68(2):1824-1843. doi: 10.1021/acs.jmedchem.4c02569.
Felix Feller 1 Irina Honin 1 Martina Miranda 1 Heiko Weber 1 Svenja Henze 1 Maria Hanl 1 Finn K Hansen 1
Affiliations

Affiliation

  • 1 Department of Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn institution, An der Immenburg 4, Bonn 53121, Germany.
Abstract

Targeted protein degradation (TPD) represents a promising alternative to conventional occupancy-driven protein inhibition. Despite the existence of more than 600 E3 Ligases in the human proteome, so far only a few have been utilized for TPD of histone deacetylases (HDACs), which represent important epigenetic Anticancer drug targets. In this study, we disclose the first-in-class Fem-1 homologue B (FEM1B)-recruiting HDAC degraders. A set of 12 proteolysis targeting chimeras (PROTACs) was synthesized using a solid-phase supported parallel synthesis approach utilizing a covalent FEM1B ligand as an E3 Ligase warhead. The evaluation of the HDAC degradation efficiency revealed substantial HDAC1 degradation by the top-performing degrader FF2049 (1g: Dmax = 85%; DC50 = 257 nM). Unlike our previously published cereblon-recruiting selective HDAC6 Degrader, A6, which uses the same HDAC ligand, the FEM1B-based PROTACs achieved selective HDAC1-3 degradation. This unexpected change in the HDAC isoform degradation profile was accompanied by significant enhancement of the antiproliferative properties.

Figures
Products